Serguei Kozlov, Ph.D., doesn’t recall if it was he who first contacted clinician Udo Rudloff, M.D., Ph.D., or Rudloff who contacted him. He just knows that their resulting two-year collaboration, which recently moved a first-in-class drug for metastatic cancer toward clinical trials, is one of the best he’s ever had.
Ira Pastan, Ph.D., says the FDA’s recent approval of moxetumomab pasudotox, a drug that originated in his lab, wasn’t like “hitting a home run with the bases loaded, all of it happening in 20 seconds.”
In fact, it was more like 20 years.
Attendees packed the Building 549 Conference Center for the National Interagency Confederation for Biological Research (NICBR) Winter Symposium, the latest in a series that aims to foster collaboration between its eight member agencies. Each symposium focuses on a specific theme, with the most recent event organized around novel therapeutics.
When NCI at Frederick began receiving royalty money from the HPV vaccine research by Doug Lowy, John Schiller, and colleagues, a portion was set aside for facilities renovations on the NCI at Frederick campus. One of the first spaces slated for renovation was Building 538, which was mainly occupied by Center for Cancer Research (CCR) scientists.
Every Monday morning, Ulrich Baxa, Ph.D., and his colleagues enter their Gaithersburg, Md., laboratory and begin calibrating their Titan Krios, a massive, $7-million transmission electron microscope that can capture high-definition images at near-atomic magnification. They load several flash-frozen biological samples into the Krios and, by 5 p.m., program the instrument to collect data. As the team leaves for the evening, the Krios begins shooting beams of energy into the samples and taking photos.
Sitting at a computer in an NCI at Frederick laboratory, Todd Hartley writes an automated method for an experiment. With a final swipe of the mouse, he clicks an on-screen button that says “Run.” The large device sitting to his left, a Biomek FXP Laboratory Automation Workstation, whirrs to life. A robotic arm hovers over a deck containing various microplates then lowers a group of pipette tips to draw liquid from a reservoir, raises and moves again, and deposits the fluid in a nearby microplate with superhuman accuracy.
A team of scientists in NCI at Frederick’s Center for Cancer Research Mouse Cancer Genetics Program and their collaborators at the University of Florence have identified a link between the presence of a growth factor receptor and cognitive impairments in patients with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).
The future of the Frederick National Laboratory (FNL) and its large initiatives was at the forefront of the recent Frederick National Laboratory Advisory Committee (FNLAC) meeting held in Shady Grove. Here are a few excerpts, accompanied by time stamps from the videocast.
Employees crowded into the Building 549 auditorium as Norman E. Sharpless, M.D., took the podium at Shady Grove, addressing NCI and contractor employees watching live and via telecast viewings. “What a difference a year makes,” he began, reflecting on how he was sworn in on the same day exactly one year ago.
Staff at NCI at Frederick will be able to participate in the Fall 2018 NCI Staff Town Hall on Wednesday, October 17, from 10:30–11:30 a.m., which will be videocast live to the Building 549 auditorium. NCI Director Norman E. “Ned” Sharpless is hosting the town hall at NCI at Shady Grove, his second since becoming director in October 2017, and is expected to speak about his plans for NCI.
